OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

ASTRAZENECA DL-,25 SP.ADR/  US0463531089  /

Stuttgart
29/04/2024  15:18:54 Chg. +1.000 Volume Bid22:00:01 Ask22:00:01 Market Capitalization Dividend Y. P/E Ratio
71.000EUR +1.43% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 218.22 bill.EUR - -

Business description

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 

Management board & Supervisory board

CEO
Pascal Soriot
Management board
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr
Supervisory board
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg
 

Company data

Name: AstraZeneca plc
Address: 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom
Phone: 0800 783 0033
Fax: +44-20-7604-8151
E-mail: Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com
Internet: www.astrazeneca.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 31/12
Free Float: -
IPO date: 06/04/1999

Investor relations

Name: Andy Barnett
IR phone: +44 (0)20 3749 5000
IR Fax: -
IR e-mail: CorporateAccess@astrazeneca

Company calendar

CW 30 | 25/07/2024 Interim Report 2nd Quarter/6 Months
CW 32 | 08/08/2024 Ex-Dividend
CW 32 | 09/08/2024 Record Date
CW 37 | 09/09/2024 Dividend Payment
CW 46 | 12/11/2024 Interim Report 3rd Quarter/9 Months
 

Main Shareholders